Last reviewed · How we verify
Imipramine Hydrochloride 25 MG
At a glance
| Generic name | Imipramine Hydrochloride 25 MG |
|---|---|
| Also known as | Imipramin DAK |
| Sponsor | Jonatan Kornholt |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Tired
- Dry mouth
- Dizzy
- Migraine
- Headache
- Stomach cramps
Key clinical trials
- Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities. (NA)
- New Treatment for Nocturnal Enuresis in Children (NA)
- Therapeutic Efficacy in Women With Stress Urinary Incontinence (PHASE3)
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study (PHASE3)
- Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter? (PHASE1)
- Dichotic Listening as a Predictor of Medication Response in Depression (PHASE1, PHASE2)
- Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imipramine Hydrochloride 25 MG CI brief — competitive landscape report
- Imipramine Hydrochloride 25 MG updates RSS · CI watch RSS
- Jonatan Kornholt portfolio CI